This week, seven of those compounds go before the FDA's Pharmacy Compounding Advisory Committee at the White Oak Campus, where AAPM is presenting the case for their inclusion on the 503A Bulk Drug Substances List
1991;49(23):L189-94
Each injection provides targeted nutrient support that may help with energy, skin vibrancy, immune wellness, metabolic balance, recovery or cognitive clarity
doi: 10.1186/1743-7075-11-52 210
Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
Clinical Evidence Comparison Cerebrolysin: Extensive Clinical Research Base Cerebrolysin has one of the most extensive clinical research bases of any neurotrophic agent, spanning more than three decades of human studies: Alzheimer's Disease Meta-Analysis: Gauthier et al